Kontigo Care (KONT) Q2 2025 earnings summary

Executive summary

• Revenue for Q2 2025 was 7.0 MSEK, down 5.9% year-over-year, with EBIT at -1.4 MSEK and a margin of -19.3%.

• MRR ended at 2.37 MSEK, a 2.6% sequential increase but 6.3% lower year-over-year.

• Strategic partnership signed with Feelgood and five out of six public tenders won, potentially increasing sales by 60% in key municipalities.

• Patent granted in Europe for relapse risk estimation method, strengthening IP position.

Financial highlights

• Net sales for H1 2025 totaled 14.1 MSEK, a 6.4% decrease year-over-year.

• EBIT for H1 was -1.9 MSEK (margin -13.6%), compared to 0.7 MSEK last year.

• Free cash flow for Q2 was -1.0 MSEK, improved from -1.8 MSEK last year.

• Gross margin remained high at 86.2% in Q2.

• Cash position at period end was 17.9 MSEK, with net surplus of 15.5 MSEK.

Outlook and guidance

• No formal guidance provided.

• Management expects positive revenue impact from new partnerships in H2.

• Focus remains on expanding in Sweden, Finland, and the Netherlands, and scaling product offerings.